By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751



Company News
Sarepta (SRPT) May Gain Approval for Duchenne Drug Sooner Than Feb. 26 Deadline, Says Analyst 8/26/2015 6:09:51 AM
Sarepta (SRPT) Receives Rare Pediatric Disease Designation From FDA For Eteplirsen For The Potential Treatment Of Duchenne Muscular Dystrophy 8/21/2015 9:51:02 AM
Sarepta (SRPT) Announces Formation Of Strategic & Scientific Advisory Board 8/12/2015 10:01:59 AM
Checkmate Comes Out of Stealth Mode With $20 Million and Ex-Sarepta (SRPT) Exec as Its Leader 8/12/2015 6:00:06 AM
Sarepta (SRPT) Announces Second Quarter 2015 Financial Results And Recent Corporate Developments 8/6/2015 12:05:02 PM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/3/2015 11:28:49 AM
Sarepta (SRPT) To Announce Second Quarter 2015 Financial Results And Recent Corporate Developments On August 6, 2015 7/30/2015 11:06:24 AM
Sarepta (SRPT) Announces The New England Journal of Medicine Publication Of Phase I Clinical Data Of Marburg Drug Candidate, AVI-7288, Supporting Safety Of The Pmoplus Platform 7/23/2015 10:56:28 AM
Investors Gear Up For Exciting News as FDA Sets Dates for BioMarin (BMRN) and Sarepta (SRPT) DMD Drugs 7/21/2015 6:34:03 AM
Sarepta (SRPT) and BioMarin (BMRN) Rivalry Heats Up as Sarepta Shops for Second DMD Drug 7/14/2015 6:01:16 AM